Gordian provides an in vivo drug discovery platform that uses aged animal “Patient Avatars”—models that naturally develop age‑related diseases—to screen pooled libraries of hundreds of therapeutic candidates in a process called Mosaic Screening. By integrating single‑cell sequencing, functional genomics, and AI‑driven analytics, the platform delivers quantitative efficacy data and prioritizes targets and candidates, helping pharma, biotech, and academic researchers improve the success rate of therapies for complex age‑related indications.
Funding
$60M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery for age‑related diseases relies on young animal models or simplified in vitro systems that do not capture the complex biology of aging, leading to low translation rates and costly clinical failures.
Solution
Gordian addresses this gap with an in vivo platform that uses “Patient Avatars”—aged animal models that naturally develop the target disease and closely mimic human physiology. The company creates large pooled libraries of therapeutic candidates and screens them simultaneously in each Avatar through a process called Mosaic Screening. This high‑throughput, multiplexed approach generates quantitative efficacy data directly in a disease‑relevant context. Integrated single‑cell sequencing, functional genomics, and AI‑driven analytics translate the in vivo readouts into actionable target and candidate rankings. By testing therapies where they are most likely to succeed, Gordian improves the odds of clinical success for complex, age‑related indications.
Target Audience
Primary customers are pharmaceutical and biotechnology companies, as well as academic research groups, that are developing treatments for age‑related diseases such as osteoarthritis, pulmonary fibrosis, metabolic disorders, heart failure, and neurodegeneration.
Features
- Patient Avatars: aged animal models that naturally acquire the disease phenotype, providing a human‑like physiological environment
- Mosaic Screening: pooled libraries of hundreds of therapies tested concurrently in each Avatar, enabling high‑throughput in vivo evaluation
- Integrated single‑cell and functional genomics pipelines to capture cellular responses and mechanism‑of‑action data
- AI/ML analytics that prioritize targets and candidates based on multi‑modal in vivo readouts
- Flexible therapeutic modalities supported, including small molecules, antibodies, siRNA, and AAV gene therapies
- Scalable preclinical workflow that reduces time and cost compared to traditional sequential testing